It is now clear that tumor-immune system interactions are far more complex than simple CTL-mediated tumor cell killing, and that effectively harnessing the immune system to control human cancers requires an integrated understanding of immune interactions ranging from clinically significant anti-tumor immunity, to counter-regulatory limitation of this immunity, to immune responses that actually support tumor development and survival. The overall goal of the Tumor Immunology and Immunotherapy (Til) program is to translate the understanding of the immune responses to cancer (both anti-tumor and pro-survival) into innovative approaches for the assessment and treatment of patients with cancer. To accomplish this, TH research is focused around four inter-related themes: Theme 1: Biology of immune cell cancers;Theme 2: Mechanisms of immunological tumor rejection;Theme 3;Microenvironment and host-tumor interactions and Theme 4;Immunotherapy and clinical discovery. The Program is co-led by Kelvin Lee, MD and Kunle Odunsi MD, PhD, who have strong interests in both basic and clinical/population aspects of tumor immunology and immunotherapy. Dr. Lee's leadership efforts focus on the basic and preclinical/translational research in the Program, which dovetails with Dr. Odunsi's leadership focus on the translation and clinical research efforts. The ability to translate research is a particular strength of TH, due in large part to the robust and longstanding inter-programmatic and basic science-clinical interactions. This strength has been enhanced over the last funding cycle by the establishment of the RPCI Center for Immunotherapy (CFI), led by Dr. Odunsi. The CFl houses all the RPCI immunotherapy clinical trials and infrastructure, including new cGMP production and clinical immunomonitoring facilities. These initiatives have occurred in conjunction with relocation (in 2008) of TH membership into 50,000 square feet of new contiguous laboratory space in the new RPCI Center for Pharmacology &Genetics, and the ongoing complete renovation of 36,800 sf in the Cancer Cell Center (supported by C06 RR 020132-01 A l , K. Lee PI) to house TH and CFI members. The Program is comprised of 28 members from 8 RPCI departments (Immunology, Pediatrics, Neurosurgery, Medicine, Molecular and Cellular Biology, Gynecologic Oncology, Cancer Prevention and Control, Surgical Oncology and Pathology), whose total peer-reviewed funding is $10.9M (NCI funding $3.2M) and a total funding of $14.2M. This compares to $6.9M peer reviewed/$9.0M total funding at the last renewal. Since the last renewal, 5 TH members have left the Institute and 3 others have moved to other Programs, while 15 new members (9 recruited from outside the Institute) have joined. Of the 481 publications generated over the last funding cycle, 22% are intra-programmatic and 20% are inter-programmatic, 50 publications are in journals with Impact Factor>10. The Program continues to actively translate its basic science into the clinical arena, with 16 active investigator-initiated trials currently accruing.
It has now become clear that various components ofthe immune system play opposing roles in inhibiting cancer growth as well as supporting its survival. The research ofthe Tumor Immunology and Immunotherapy Program seeks to understand how the immune system responds to cancer, and apply this understanding to new and innovative approaches to diagnose and treat patients with cancer.
|Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10|
|Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71|
|Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48|
|Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22|
|Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65|
|Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77|
|Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70|
|Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77|
|Haller, Andrew C; Tan, Wei; Payne-Ondracek, Rochelle et al. (2014) High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate 74:509-19|
|Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48|
Showing the most recent 10 out of 517 publications